Dark

Check out our API

AGE
AgeX Therapeutics, Inc.
stock NYSEAMERICAN

Inactive

Mar 26, 2024

11.10USD-11.905%(-1.50)3,753

Pre-market

0.00USD-100.000%(-12.60)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

07:21AM EST The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.15 A.M. ET). RTTNews

Dec 14, 2021

08:37AM EST AgeX To Collaborate With University Of California, Irvine, On Research Program On Certain Brain Disorders RTTNews

08:36AM EST AgeX Therapeutics to Collaborate With University of California, Irvine, On Research Program For Exosome-Based Therapies For Certain Brain Disorders Benzinga

Nov 30, 2021

04:48PM EST AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed With IMS001 Benzinga

Nov 24, 2021

07:32AM EST The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension Benzinga

Nov 23, 2021

04:10PM EST AgeX Therapeutics Receives Stock Exchange Deficiency Letter Benzinga

Nov 15, 2021

09:26AM EST AgeX Therapeutics Q3 EPS $(0.05) Up From $(0.07) YoY Benzinga

Nov 12, 2021

04:17PM EST AgeX Therapeutics Q3 Loss/share $0.05 Vs. Loss $0.07 Year Ago RTTNews

04:05PM EST AgeX Therapeutics Reports Third Quarter 2021 Financial Results Business Wire

Aug 13, 2021

04:15PM EDT AgeX Therapeutics Q2 Loss/share $0.07, Same As Last Year RTTNews

04:06PM EDT AgeX Therapeutics Q2 EPS $(0.07), Same YoY, Sales $37.00K Down From $414.00K YoY Benzinga

04:05PM EDT AgeX Therapeutics Reports Second Quarter 2021 Financial Results Business Wire

Jul 26, 2021

06:07AM EDT A Peek Into The Markets: US Stock Futures Down Following Friday's Rally Benzinga

Jul 23, 2021

04:15PM EDT AgeX Therapeutics, LyGenesis Terminate Merger Talks Benzinga

04:15PM EDT AgeX Therapeutics and LyGenesis Terminate Merger Negotiations Business Wire

May 17, 2021

04:47PM EDT AgeX Therapeutics Q1 EPS $(0.05) Up From $(0.08) YoY Benzinga

04:08PM EDT AgeX Therapeutics Q1 Loss/share $0.06 Vs. Loss $0.08 Year Ago RTTNews

04:05PM EDT AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire

Mar 31, 2021

04:17PM EDT AgeX Therapeutics Reports FY20 EPS $(0.29) Up From $(0.33) YoY, Sales $1.9M Up From $1.7M YoY Benzinga

04:05PM EDT AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update Business Wire

Mar 12, 2021

08:07AM EST AgeX Therapeutics Announces Online Publication Of Data Relating To Regeneration, Aging, And Cancer In BioRxiv RTTNews

08:03AM EST AgeX Therapeutics Reports Online Publication Of Data Related To Regeneration, Aging, Cancer In bioRxiv Benzinga

08:00AM EST AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer Business Wire

Mar 10, 2021

12:08PM EST AgeX Therapeutics Granted EU Patent Titled 'COMPOSITIONS FOR USE IN THE TREATMENT OF WOUNDS IN MAMMALIAN SPECIES' Benzinga

08:14AM EST AgeX Therapeutics To Collaborate With Ohio State University To Generate Proof-Of-Concept Animal Data For Co.'s Brown Adipose Tissue Cell Therapy Candidate For Diabetes, Obesity Benzinga

08:05AM EST AgeX Therapeutics To Partner With The Ohio State University RTTNews

08:00AM EST AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity Business Wire

Mar 2, 2021

08:13AM EST AgeX Therapeutics Reports Will Proceed To Negotiate Deal For Merger With LyGenesis Benzinga

08:00AM EST AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement Business Wire

Dec 22, 2020

03:08PM EST AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only Business Wire

Nov 16, 2020

04:09PM EST AgeX Therapeutics Q3 Loss/share $0.07 Vs. Loss $0.09 Year Ago RTTNews

04:05PM EST AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire

Oct 28, 2020

08:07AM EDT AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 To ImStem Biotechnology Tor Development Of Cell Therapy Candidate IMS001 For COVID-19 And Acute Respiratory Distress Syndrome Benzinga

08:04AM EDT AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 To ImStem Biotechnology RTTNews

08:00AM EDT AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome Business Wire

Oct 10, 2020

03:08AM EDT Mid-Morning Market Update: Markets Open Higher; AMD Nears Deal To Buy Xilinx Benzinga

03:08AM EDT Mid-Day Market Update: Gold Gains 2%; ShiftPixy Shares Plunge Benzinga

Oct 9, 2020

11:13AM EDT Mid-Morning Market Update: Markets Open Higher; AMD Nears Deal To Buy Xilinx Benzinga

Oct 8, 2020

02:30PM EDT Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Consumer Portfolio Services Shares Spike Higher Benzinga

12:45PM EDT Mid-Day Market Update: Eaton Vance Jumps Following Acquisition News; Cytokinetics Shares Plunge Benzinga

Sep 15, 2020

08:00AM EDT Rockwell Medical Announces Appointment of Russell L. Skibsted as GlobeNewswire Inc

Sep 9, 2020

08:29AM EDT Newgioco Obtains GLI-33 Certification To Launch Elys Sportsbook Platform In U.S. Benzinga

08:27AM EDT AgeX Therapeutics, Lineage Cell Therapeutics Announce Expansion Of Agreement Related To ESI Clinical-Grade Pluripotent Stem Cell Lines For Therapeutic Purposes Benzinga

08:06AM EDT AgeX Therapeutics, Lineage Announce Broadening Of Collaborative Relationship With Regard To ESI Stem Cell Lines RTTNews

08:00AM EDT AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes Business Wire

Aug 14, 2020

04:16PM EDT AgeX Therapeutics Q2 Loss/share $0.07 Vs. Loss $0.08 Year Ago RTTNews

04:08PM EDT AgeX Therapeutics Q2 EPS $(0.07) Up From $(0.08) YoY Benzinga

04:05PM EDT AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire

Share